| Course | NU 631 Healthcare of Women across the Lifespan |
|---|---|
| Unit | Unit 6 |
| Paper type | Menopause management plan |
| Length | About 1,020 words, 6 pages |
| Format | APA 7 student paper |
| School | Herzing University |
| Program | MSN Family Nurse Practitioner |
| Updated | October 2026 |
Free sample paper for NU 631 Unit 6
Menopause Management Plan for a 52-Year-Old With Severe Vasomotor Symptoms 18 Months After Her Final Period
Student Name
Department of Nursing, Herzing University
NU 631: Healthcare of Women across the Lifespan
Instructor Name
March 2, 2026
Menopause Management Plan for a 52-Year-Old With Severe Vasomotor Symptoms 18 Months After Her Final Period
Her Symptoms and What They Cost Her
Ms. G., a composite 52-year-old sales director, had her final menstrual period 18 months ago. She has 10 to 12 hot flashes a day, several lasting two to three minutes with drenching sweat, and wakes three to four times a night soaked, changing her shirt twice. In her words: "I'm exhausted, I'm snapping at my team, and I dread presenting because I turn red and sweat through my blouse." She rates the bother as 9 out of 10. She has used layered clothing, a fan, and cut out alcohol and spicy food, with little change. She also notes vaginal dryness with some discomfort during intercourse. The severity and the effect on her sleep and work, not the presence of symptoms alone, are what justify considering treatment.
History Bearing on Risk
Cardiovascular: blood pressure 124/78; lipids normal; nonsmoker; no diabetes; estimated 10-year cardiovascular risk low, under 5%. Thrombotic: she has never had a blood clot, and neither has anyone in her family; body mass index 27. Breast: mammogram eight months ago normal; no personal history of breast cancer; her aunt was diagnosed at 70; no known inherited mutation in the family. Bone: no fractures; her mother had a hip fracture at 78. Uterus: intact, no abnormal bleeding since her final period. Liver disease: none. Migraine: none. These factors are gathered together because the decision depends on how they combine, not on any one of them.
Options by Symptom and Strength of Evidence
For vasomotor symptoms: hormone therapy is the most effective treatment, reducing hot flash frequency by about three quarters and improving sleep disrupted by night sweats (The North American Menopause Society [NAMS], 2022). Because her uterus is intact, estrogen must be combined with a progestogen to protect the endometrium. Transdermal estradiol is preferred over oral estrogen when thrombotic or cardiovascular risk is a consideration, because observational evidence suggests a lower risk of venous thromboembolism with the transdermal route.
Nonhormonal options with good evidence: fezolinetant 45 mg daily, a neurokinin 3 receptor antagonist that reduced the frequency and severity of moderate to severe hot flashes in a randomized trial (Lederman et al., 2023), which requires liver function testing before and during treatment; low-dose paroxetine 7.5 mg at bedtime, approved for vasomotor symptoms; and gabapentin, which can help night sweats and sleep. Cognitive behavioral therapy reduces how bothersome hot flashes are, although it has less effect on their frequency. Options with poor evidence, including most herbal products, were discussed and not recommended.
For vaginal dryness: low-dose vaginal estrogen is effective and has minimal systemic absorption; vaginal moisturizers and lubricants are also effective for mild symptoms.
Individualizing the Risk-Benefit Balance
Much of the fear about hormone therapy comes from the initial Women's Health Initiative results in 2002, which reported increased risks of coronary events, stroke, venous thromboembolism, and breast cancer with oral conjugated estrogens plus medroxyprogesterone acetate in women whose average age was 63 (Writing Group for the Women's Health Initiative Investigators, 2002). Later analyses by age showed that absolute risks were considerably lower in women aged 50 to 59 than in older women (Manson et al., 2013). Current guidance concludes that for women younger than 60 or within 10 years of their final period, without contraindications, the benefits of hormone therapy for bothersome vasomotor symptoms generally outweigh the risks (NAMS, 2022). Ms. G. is 52, 18 months from her final period, at low cardiovascular and thrombotic risk, and without a history of breast cancer. For her, the balance favors treatment. Her aunt's breast cancer at 70 is a second-degree relative diagnosed late, which is not a contraindication.
Honest risk information was still given: combined estrogen and progestogen therapy is associated with a small increase in breast cancer risk with longer use, and all hormone therapy carries a small increase in stroke and thrombosis risk, lower with transdermal estrogen. These were presented as small absolute changes relevant to her, not as the population-level figures from the 2002 report.
Decision
Ms. G. chose hormone therapy: transdermal estradiol 0.05 mg per day, as a patch changed twice weekly, with micronized progesterone 100 mg by mouth nightly, taken continuously for endometrial protection. She was told to expect some irregular spotting while her body adjusts during the first months, which usually settles, and that bleeding after six months, or heavy bleeding at any time, needs evaluation. For vaginal dryness, she will start with a vaginal moisturizer and add low-dose vaginal estradiol if needed. She was told that if she prefers to stop hormones later, fezolinetant or paroxetine remain options.
What She Was Told About Stopping
Ms. G. asked how long she would need the patch and what happens when she stops. She was told that hot flashes return in about half of women when hormone therapy is stopped, regardless of whether it is stopped suddenly or gradually, and that there is no fixed date by which she must stop. When she decides to try stopping, the dose can be reduced over a few months so she can judge whether her symptoms have eased on their own. She was also told that stopping would not undo any benefit already gained and would remove the small added risks within a few years. Writing this down at the start means the decision about duration is hers and is made with information rather than with a rule she half remembers from a magazine.
Monitoring, Duration, and Review
Review in three months: symptom frequency and bother, sleep, bleeding pattern, blood pressure, and side effects such as breast tenderness; dose adjusted to the lowest dose that controls her symptoms. Then annual review: continued need, breast screening per schedule, blood pressure, and any new risk factors such as a thrombotic event, a new cardiovascular diagnosis, or a breast cancer diagnosis in a close relative. Duration is not fixed at an arbitrary number of years; the decision to continue is revisited each year based on her symptoms, goals, and risk (NAMS, 2022). Bone density testing will be considered at 65, or earlier if a risk assessment indicates.
References
Lederman, S., Ottery, F. D., Cano, A., Santoro, N., Shapiro, M., Stute, P., Thurston, R. C., English, M., Franklin, C., Lee, M., & Neal-Perry, G. (2023). Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): A phase 3 randomised controlled study. The Lancet, 401(10382), 1091-1102. https://doi.org/10.1016/S0140-6736(23)00085-5
Manson, J. E., Chlebowski, R. T., Stefanick, M. L., Aragaki, A. K., Rossouw, J. E., Prentice, R. L., Anderson, G., Howard, B. V., Thomson, C. A., LaCroix, A. Z., Wactawski-Wende, J., Jackson, R. D., Limacher, M., Margolis, K. L., Wassertheil-Smoller, S., Beresford, S. A., Cauley, J. A., Eaton, C. B., Gass, M., ... Wallace, R. B. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA, 310(13), 1353-1368. https://doi.org/10.1001/jama.2013.278040
The North American Menopause Society. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767-794. https://doi.org/10.1097/GME.0000000000002028
Writing Group for the Women's Health Initiative Investigators. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA, 288(3), 321-333. https://doi.org/10.1001/jama.288.3.321
NU 631 Unit 6 instructions, in plain terms
For Unit 6 you write a management plan for a woman with menopausal symptoms, usually from a case. Expect to describe her symptoms and their impact, then review the history that affects treatment risk, including cardiovascular, thrombotic and breast cancer risk. Options should be presented by symptom with the strength of evidence for each, including hormonal, non-hormonal and lifestyle approaches. Many sections ask you to explain the risk-benefit balance for this patient using current evidence. The chosen treatment should be written in full with dose, route and any progestogen needed for endometrial protection. Duration, stopping and monitoring are commonly required. Cite position statements and major trials in APA 7. Use a composite patient. Your instructor may also want the patient's own words about what matters, which can make the decision section stronger.
How this NU 631 Unit 6 example is built
The plan opens with her symptoms counted and their effects on sleep and work described. The risk history section lists blood pressure, lipids, estimated cardiovascular risk, clotting history, breast history and a uterus still present, which means a progestogen is needed. Options are grouped by symptom, with hormone therapy as the most effective for hot flashes and non-hormonal medicines and behavioral approaches as alternatives with their evidence. The individualizing section explains how risk differs by age and years since menopause and why the transdermal route lowers clotting risk. The decision section gives estradiol by patch at a stated dose with micronized progesterone nightly. Her question about stopping is answered honestly, noting symptoms may return. Monitoring sets a three-month review of symptoms, bleeding, blood pressure and side effects, then yearly review.
Where the points sit in the NU 631 Unit 6 rubric
A Herzing rubric for a menopause plan typically rewards symptom assessment, risk assessment, presentation of options, individualized risk-benefit reasoning, the treatment plan, monitoring and evidence. Risk assessment points require cardiovascular, thrombotic and cancer factors to be considered. Options are credited when evidence strength is shown for each. Individualized reasoning matters most, so graders want the current interpretation of the trial data applied to this patient's age and timing. Treatment plan points depend on complete dosing, the correct progestogen for a woman with a uterus and route chosen with reasons. Monitoring is credited when review timing and what is checked are specific. Evidence points require current position statements in APA format. Writing points cover balanced, accurate language about risks.
NU 631 Unit 6 help before you submit
Menopause plans often lose points by repeating the early Women's Health Initiative headlines without the later analysis by age and time since menopause. Students also forget the progestogen for women with a uterus. Route of estrogen is frequently chosen without considering clotting or cardiovascular risk. Non-hormonal options are sometimes left out, though many rubrics expect them. Plans also slip when they give no duration or review, or one that sets an arbitrary stopping age. Doses are often missing. Some papers present hormone therapy as either dangerous or harmless, when the evidence calls for a balanced view tied to the patient. Finally, include what she was told about stopping, since symptoms often return.
Get a NU 631 Unit 6 example written to your instructions
Send the Unit 6 instructions and the rubric from your NU 631 classroom, plus the patient case your plan covers. We write a custom example that records symptom impact, individualizes the risk balance and sets a review, returned in 24 to 48 hours. The first custom sample is free.
More NU 631 papers and FNP samples
- NU 631 Unit 1: Well-woman visit plan
- NU 631 Unit 2: Contraception counseling record
- NU 631 Unit 3: Preconception counseling plan
- NU 631 Unit 4: Prenatal care plan
- NU 631 Unit 5: Abnormal screening result algorithm
- NU 631 Unit 7: Safety screening and response protocol
- NU 631 Unit 8: Maternal morbidity case review
- NU 636 Unit 6: Discussion post
- NU 623 Unit 6: Referral and consultation letter
- NU 627 Unit 6: Goals of care conversation record
- NU 632 Unit 6: Adolescent confidentiality and consent plan
NU 631 Unit 6 questions, answered
Why is the evidence base here treated so carefully?
Because earlier trial reporting was subsequently reanalyzed, and the risk picture that reached general awareness differs from what current guidance says, particularly by age and timing. Secondary summaries written in the intervening period still circulate. Work from current primary guidance, note the version, and be explicit that this is an area where older figures remain in wide use.
Does symptom presence justify treatment?
Impact does. Many patients experience symptoms that do not disturb them enough to warrant intervention, and treatment decisions rest on how much the symptoms interfere with sleep, work, mood and relationships. Recording severity and effect gives the plan a defensible basis, whereas a symptom list alone leaves the indication unstated.
Should non-hormonal options be included?
Always, because some patients cannot use hormonal treatment and others simply prefer not to. Present what the evidence supports for each specific symptom rather than offering alternatives as a lesser category, and be honest about effect sizes. A plan with no alternative leaves those patients with nothing, which is neither good practice nor a complete answer.
Where can I find a free NU 631 Unit 6 sample paper?
The full NU 631 Unit 6 menopause plan is on this page for free, with her risk history, options by evidence, the reinterpreted trial data, the chosen regimen and monitoring. For a different patient, ask us for a custom menopause plan, which we write free and generally send within two days.
Is hormone therapy safe for menopause symptoms?
For healthy women under 60 or within ten years of menopause, current position statements say the benefits of hormone therapy for bothersome hot flashes usually outweigh the risks. The decision depends on cardiovascular, clotting and breast cancer risk, and transdermal estrogen carries lower clotting risk.